Studies on the difference in the circumstances and the diseases between Japanese and Chinese

用超声心动图初步研究了各种降压药物对左室心肌肥厚的影响，结果表明，钙拮抗剂、血管紧张素转换酶抑制剂、α_2受体阻滞剂和中枢交感神经舒张剂能有效地缓解这种情况，但β受体阻滞剂的作用是不可预测的，利尿剂和直接血管扩张剂则没有作用。然而，降压药物的效果因种族而异，很少有研究将降压药物对心肌肥厚的影响进行国际比较。此外，MRI作为一种测量左心室重量的方法也引起了人们的注意，将MRI的结果与常规心电图术和超声心动图的结果进行比较是很有趣的。这项研究旨在通过核磁共振成像和超声心动图…来评估各种降压药物在日本和中国受试者中的抗心肌肥厚作用。目的：应用磁共振成像(MRI)和超声心动图(ECHO)，观察血管紧张素II 1型受体特异性拮抗剂TCV-116对高血压病患者血流动力学和心肌肥厚的影响。电影MRI图像采用梯度回波技术GRASS，回波时间13毫秒，重复时间66毫秒，翻转角20度。MRI测量左室容量和质量采用Simpson法则。用Teichholz公式计算超声心动图的左心室容量。使用美国超声心动图测量学会和Devereux等人的公式测量超声心动图测量的左心室质量(LVM)。：lvm=0.8[1.04(IVS+LVID+PWT)^3-LVID^3)]+0.6g.(IVS：室间隔厚度，PWT：后壁厚度，LVID：左心室内径)结果：TCV-116终日剂量分别为8 mg 7例，4 mg 3例，2 mg 2例。用药后，收缩压从185×19降至161×30毫米汞柱，舒张压从108×10降至96×13(n=12，P<0.005)，心率从70×12降至70×9次/分(n=12，NS)。MRI和ECHO均显示应用TCV-116后LVm显著降低(n=12，p&lt；0.05)。MRI显示TSR由1888×473降至1702×408 dynes-sec-cm；-5&gt；(n=11，p&lt；0.05)。结论：住院高血压病患者口服TCV-116 2~8 mg/d，连续服药8~12周，血压下降，心肌肥厚消退。其他血流动力学参数未见明显变化。将进行上述测试，并在进一步研究中比较中日两国受试者的效果。较少

Studies on the effects of various hypotensive drugs on left ventricular myocardial hypertrophy primarily by echocardiography have shown that calcium antagonists, angiotensin-converting enzyme inhibitors, alpha_2-blockers, and central sympatholytic drugs are effective for attenuating the condition, but that the effects of beta-blockers are unpredictable, and diuretics and direct vasodilators have no effects. However, the effects of hypotensive drugs have been suggested to vary among races, and there have been few studies in which the effects of hypotensive drugs on cardiac hypertrophy were compared internationally. Also, MRI has attracted attention as a method for measurement of the left ventricular weight, and comparison of the findings by MRI with those by conventional electrocardiography and echocardiography is interesting. This study is designed to evaluate anti-cardiac hypertrophy effects of various hypotensive drugs in Japanese and Chinese subjects by MRI as well as by echocaardio … More graphy and MRI.Objectives : Using cinemagnetic resonance imaging(MRI)and echocardiography(ECHO), we studied the effects of TCV-116, a specific antagonist for angiotensin II subtype 1 receptors, on hemodynamics and cardiac hypertrophy in patients with essential hypertension.Subjects and Methods : Twelve patients with essential hypertension received oral TCV-116 after a control period of placebo administration. Cine MRI images were acquired in the axial plane with a gradientecho technique, GRASS, with echo time of 13 msec, repetition time of 66 msec, and flip angle of 20 degrees. Simpson's rule was used forleft ventricular volume and mass measurements by MRI. Left ventricular volumes by ECHO were calculated using Teichholz's formula. Left ventricular mass(LVM)by ECHO was measured using American Society of Echocardiography measurements and the formula by Devereux et al. : LVM=0.8[1.04(IVS+LVID+PWT)^3-LVID^3)]+0.6g. (IVS : interventricularseptal thickness, PWT : posterior wall thickness, LVID : left ventricular internal dimension)Results : Final daily doses of TCV-116 were 8 mg in 7 patients, 4 mg in 3 patients and 2 mg in 2 patients. After TCV-116 administration, systolic BP decreased from 185*19(mean*SD)to 161*30 mmHg and diastolic BP from 108*10 to 96*13(n=12, p<0.005)while HR remained unchanged from 70*12 to 70*9 bpm(n=12, NS). Both MRI and ECHO revealed a significant decrease in LVM after TCV-116 administration(n=12, p<0.05). MRI revealed a significant decrease in TSR from 1888*473 to 1702*408 dynes-sec-cm^<-5>(n=11, p<0.05). No significant changes were observed in other hemodynamic parameters before and after TCV-116 administration.Conclusions : Inpatients with essential hypertension, TCV-116 administered orally at doses of 2-8 mg/day for 8-12 weeks reduced blood pressure and led to a regression of cardiac hypertrophy. No deficient changes were observed in other hemodynamic parameters.The above tests will be carried out and effects will be compared between Japanese and Chinese subjects in further studies. Less